Clinical use of liposomal and lipid-complexed amphotericin B
| Autor: | S. de Marie, R. Janknegt, Irma A. J. M. Bakker-Woudenberg |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Pharmacology
Microbiology (medical) Drug Carriers Liposome Dose business.industry Comparative trial Lipids Infectious Diseases Therapeutic index Pharmacokinetics Amphotericin B Liposomes Toxicity medicine Animals Humans Pharmacology (medical) Amphotericin B Colloidal Dispersion business medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 33:907-916 |
| ISSN: | 1460-2091 0305-7453 |
| Popis: | Encapsulation of amphotericin B in liposomes or complexing of the compound with other lipid carriers brings about a major reduction in toxicity. Although animal experimental studies have shown an increased therapeutic index for a variety of such lipid formulations resulting in higher dose-dependent efficacy rates, clinical data on pharmacokinetics and efficacy are still scanty. AmBisomeR, Amphotericin B Lipid Complex (ABLC) and AmphocilR (Amphotericin B Colloidal Dispersion, ABCD) have quite different structural and pharmacokinetic characteristics; however, it is not clear whether these differences are important with respect to tolerance and efficacy. At this moment, most published clinical data are available for AmBisomeR, which shows encouraging results in a variety of invasive fungal infections. AmBisomeR has been safely administered in high dosages up to 5 mg/kg/day. Randomized comparative trials with liposomal and other lipid-complexed amphotericin B formulations versus conventional amphotericin B are urgently needed to assess their respective clinical values. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|